Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers
Status:
Active, not recruiting
Trial end date:
2022-07-05
Target enrollment:
Participant gender:
Summary
This study will test any good and bad effects of the study drug called enzalutamide.
Enzalutamide could shrink the cancer but it could also cause side effects. Researchers hope
to learn if the study drug will shrink the cancer by at least 30% compared to its present
size, in at least 1 out of 5 patients. Enzalutamide is not FDA approved to treat salivary
gland cancer, but it has already been FDA-approved to treat other cancers.
Phase:
Phase 2
Details
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborators:
Astellas Pharma US, Inc. National Cancer Institute (NCI)